Lewy Body Disease: Complete ICD-11 Coding Guide

1. Introduction

Lewy body disease represents one of the greatest diagnostic and therapeutic challenges in contemporary neurology. As the second most common form of neurodegenerative dementia in elderly individuals, surpassed only by Alzheimer's disease, this condition affects millions of people globally and frequently remains underdiagnosed or confused with other dementias.

Characterized histologically by the presence of intracytoplasmic eosinophilic neuronal inclusions called Lewy bodies, this disease presents a distinctive clinical triad that combines fluctuating cognitive decline, recurrent visual hallucinations, and parkinsonism. The complexity of its clinical presentation, which can mimic both Alzheimer's disease and Parkinson's disease, makes precise knowledge of its characteristics fundamental for appropriate coding.

The importance of correct coding transcends merely administrative aspects. Accurate coding directly impacts therapeutic planning, resource allocation in health systems, epidemiological research, and the development of public policies aimed at neurodegenerative diseases. Healthcare professionals who understand the nuances of Lewy body disease and its appropriate coding contribute significantly to better care for patients and their caregivers, in addition to generating more reliable data for clinical research and health management.

2. Correct ICD-11 Code

Code: 8A22

Description: Lewy body disease

Parent category: Disorders with neurocognitive impairment as a main feature

Official definition: Lewy body disease is a neurodegenerative disorder and the second most common form of dementia in the elderly after Alzheimer's disease. Lewy bodies are histologically defined as eosinophilic intracytoplasmic neuronal inclusions in the cortex or brainstem.

This specific ICD-11 code was developed to precisely capture this distinct nosological entity, recognizing its particular clinical, neuropathological, and evolutionary characteristics. The classification reflects the contemporary understanding that Lewy body disease is not simply a variant of other dementias, but a condition with its own pathophysiology, clinical presentation, and prognosis. The correct use of this code facilitates epidemiological tracking, allows for international comparisons, and contributes to the development of specific clinical guidelines for this patient population.

3. When to Use This Code

Code 8A22 should be applied in specific clinical scenarios where the central features of Lewy body disease are present:

Scenario 1: Dementia with cognitive fluctuations and visual hallucinations A 72-year-old patient presents with progressive cognitive decline over 18 months, with periods of mental confusion alternating with moments of relative lucidity throughout the same day. Reports seeing children playing in his room and animals that do not exist, with detailed and vivid descriptions. Neuropsychological evaluation demonstrates attentional and executive deficits disproportionate to memory deficits.

Scenario 2: Parkinsonism associated with early dementia Patient develops mild parkinsonian symptoms (bradykinesia, rigidity) and, within one year, presents with significant cognitive decline with recurrent visual hallucinations. The temporal sequence is crucial: when dementia occurs simultaneously or within one year after motor symptoms, the diagnosis of Lewy body disease is more appropriate than Parkinson disease with dementia.

Scenario 3: REM sleep behavior disorder preceding dementia Patient with history of violent behaviors during sleep (shouting, punching, kicking) for several years, subsequently developing fluctuating cognitive decline and parkinsonian symptoms. REM sleep behavior disorder is frequently an early marker of Lewy body disease.

Scenario 4: Neuroleptic hypersensitivity Elderly patient with dementia who developed severe adverse reaction to typical antipsychotics, with marked worsening of motor status and decreased level of consciousness. This characteristic hypersensitivity, combined with cognitive fluctuations and visual hallucinations, strengthens the diagnosis.

Scenario 5: Autonomic dysfunction associated with fluctuating dementia Patient presents with frequent falls, significant orthostatic hypotension, severe constipation and early urinary incontinence, accompanied by cognitive decline with marked daily fluctuations and well-formed visual hallucinations.

Scenario 6: Confirmation by specific biomarkers Patient with clinical suspicion of dementia who presents with reduced uptake on cardiac MIBG scintigraphy or occipital hypoperfusion on functional neuroimaging studies, associated with the presence of central clinical features of the disease.

4. When NOT to Use This Code

It is essential to recognize situations where code 8A22 is not appropriate, avoiding diagnostic confusion:

Parkinson disease with late dementia: When parkinsonian motor symptoms precede cognitive decline by more than one year (usually several years), the appropriate diagnosis is Parkinson disease with dementia, not Lewy body disease. The temporal rule of "one year" is an essential differential criterion.

Alzheimer dementia with psychotic symptoms: Patients with Alzheimer disease may develop hallucinations, but typically these occur in more advanced stages, are not predominantly visual, and there is neither characteristic cognitive fluctuation nor significant early parkinsonism.

Delirium superimposed on other dementias: Acute cognitive fluctuations secondary to infections, metabolic disturbances, or medications in patients with prior dementia do not characterize Lewy body disease. Delirium is transient and has an identifiable cause.

Primary psychiatric disorders: Visual hallucinations in the context of schizophrenia, bipolar disorder, or psychotic depression, without progressive cognitive decline or parkinsonism, do not justify this code.

Vascular dementias: Even when there are cognitive fluctuations related to multiple cerebrovascular events, the absence of typical visual hallucinations, parkinsonism, and other core features excludes the diagnosis of Lewy body disease.

5. Step-by-Step Coding Process

Step 1: Assess diagnostic criteria

The clinical diagnosis of Lewy body disease is based on the identification of core and suggestive features. Confirm the presence of progressive cognitive decline that interferes with functional activities. Next, identify at least two of the three core features:

Cognitive fluctuations: Pronounced variations in attention and alertness, with periods of confusion alternating with lucidity
Recurrent visual hallucinations: Well-formed, detailed, often involving people or animals
Spontaneous parkinsonism: Bradykinesia, rigidity, or tremor, not attributable to medications

Useful instruments include comprehensive neuropsychological assessment, specific scales for cognitive fluctuation, detailed neurological examination, and structured questionnaires about REM sleep symptoms.

Step 2: Verify specifiers

Evaluate suggestive features that increase diagnostic probability:

REM sleep behavior disorder confirmed by polysomnography or robust clinical history
Severe neuroleptic sensitivity
Autonomic dysfunction not explained by other causes
Occipital hypoperfusion on functional neuroimaging
Reduced uptake on cardiac scintigraphy with MIBG

Document the severity of cognitive impairment (mild, moderate, severe) and the degree of functional dependence, as these aspects influence therapeutic planning and prognosis.

Step 3: Differentiate from other codes

8A20 - Alzheimer disease: Characterized by prominent and early episodic memory deficit, gradual progression without marked fluctuations, absence of typical visual hallucinations in early phases, and absent or late parkinsonism. Neuroimaging shows hippocampal and temporoparietal atrophy.

8A21 - Progressive focal atrophies: Present specific clinical syndromes with focal deficits (primary progressive aphasia, progressive apraxia, corticobasal syndrome) without the cognitive fluctuations, visual hallucinations, or symmetric parkinsonism characteristic of Lewy body disease.

8A23 - Frontotemporal lobar degeneration: Manifests with prominent behavioral and personality changes or progressive aphasia, typically with onset before age 65, without cognitive fluctuations, visual hallucinations, or parkinsonism in early phases.

Step 4: Required documentation

Essential checklist:

Detailed clinical history with symptom chronology
Specific description of cognitive fluctuations (frequency, duration, pattern)
Characterization of hallucinations (type, content, frequency, patient reaction)
Neurological examination with documentation of parkinsonian signs
Formal neuropsychological assessment
Investigation of REM sleep behavior disorder
Structural neuroimaging studies
Exclusion of secondary causes (metabolic, infectious, medication-related)
Response to medications (particularly neuroleptics if used)

6. Complete Practical Example

Clinical Case

Mr. J.M., 74 years old, retired, is brought by his wife to a neurology consultation due to progressive "forgetfulness and mental confusion" for approximately two years. His wife reports that the patient has days when he seems "normal," conversing appropriately and performing usual activities, but at other times, especially in the late afternoon, he becomes confused, disoriented, and does not recognize family members.

Over the past eight months, the patient began reporting seeing small children playing in his living room, describing them in detail, including clothing and toys. Initially, his wife thought these were delusions, but she noticed that the patient describes these visions consistently and calmly. He also reports seeing a black dog entering through the door, although they do not have any pets.

His wife mentions that approximately three years ago, before the memory problems, the patient began having nocturnal episodes where he shouts, moves his arms violently, and appears to be fighting something, even falling out of bed. These episodes occur during sleep, and the patient reports vivid dreams of being attacked.

In the past year, family members noticed that the patient walks more slowly, with short steps, and has difficulty getting up from a chair. His facial expression became less animated. There have been three falls with no apparent cause in the past six months.

On neurological examination: patient alert during consultation, oriented to person and place, but with difficulty pinpointing the date. Mini-Cog State Examination: 22/30 points, with difficulties in attention, calculation, and executive function, but relatively preserved recall memory (2/3 words). He presents bilateral bradykinesia, cogwheel rigidity in upper limbs, without evident tremor. Gait with short steps and reduced arm swing. Documented orthostatic hypotension (25 mmHg drop in systolic pressure upon standing).

Brain magnetic resonance imaging shows mild diffuse cortical atrophy, without significant hippocampal atrophy, without relevant vascular lesions. Formal neuropsychological evaluation confirms attentional and executive deficits disproportionate to memory deficits.

Step-by-Step Coding

Criteria analysis:

Progressive cognitive decline: Confirmed by two-year history of evolution with functional impact
Core features present:
- Cognitive fluctuations: Marked daily variations between confusion and relative lucidity
- Recurrent visual hallucinations: Well-formed visions of children and animals, detailed and consistent
- Parkinsonism: Bradykinesia, rigidity, gait alteration, not attributable to medications
Suggestive features:
- REM sleep behavior disorder: Highly suggestive history of violent behaviors during sleep with vivid dreams
- Autonomic dysfunction: Significant orthostatic hypotension, frequent falls
Exclusion of alternative diagnoses:
- No disproportionate episodic memory deficit (does not suggest Alzheimer's)
- Motor and cognitive symptoms began simultaneously (excludes Parkinson's with dementia)
- Without prominent behavioral or personality changes (excludes frontotemporal degeneration)
- No evidence of significant vascular disease

Code selected: 8A22 - Lewy body disease

Complete justification:

The patient presents the characteristic clinical triad of Lewy body disease: cognitive decline with marked fluctuations, recurrent well-formed visual hallucinations, and spontaneous parkinsonism. The presence of all three core features confers high diagnostic probability. Additionally, REM sleep behavior disorder preceding cognitive symptoms and autonomic dysfunction reinforce the diagnosis. The neuropsychological profile with attentional and executive deficits disproportionate to memory deficits is typical. The absence of significant hippocampal atrophy rules out Alzheimer's disease as the primary diagnosis.

Applicable complementary codes:

Codes for specific symptoms (falls, REM sleep disorder) may be added as needed for administrative purposes
Codes for identified comorbidities

7. Related Codes and Differentiation

Within the Same Category

8A20: Alzheimer's Disease

When to use 8A20 vs. 8A22: Use 8A20 when episodic memory deficit is the predominant and initial feature, with gradual and insidious progression, without marked cognitive fluctuations. Patients with Alzheimer's typically do not present visual hallucinations in early stages, and when present, they occur in advanced stages. Parkinsonism, if present, emerges late.

Main difference: Alzheimer's disease is characterized by progressive amnesia as a cardinal symptom, whereas Lewy body disease presents cognitive fluctuations, visual hallucinations, and parkinsonism as central features from early stages.

8A21: Progressive focal atrophies

When to use 8A21 vs. 8A22: Use 8A21 when there are specific focal syndromes such as primary progressive aphasia (isolated language difficulty), progressive apraxia (difficulty performing voluntary movements), or corticobasal syndrome (asymmetric rigidity, apraxia, alien limb phenomenon).

Main difference: Progressive focal atrophies manifest with specific and focal neurological or cognitive deficits, without the combination of fluctuations, visual hallucinations, and symmetric parkinsonism typical of Lewy body disease.

8A23: Frontotemporal lobar degeneration

When to use 8A23 vs. 8A22: Use 8A23 when behavioral changes (disinhibition, apathy, loss of empathy, compulsive behaviors) or progressive aphasia are prominent and early manifestations, typically in younger patients (before age 65).

Main difference: Frontotemporal degeneration is characterized by personality and behavioral changes or language alterations as initial symptoms, whereas Lewy body disease presents with fluctuating cognitive decline with visual hallucinations and parkinsonism.

Differential Diagnoses

Parkinson's disease with dementia: Temporal differentiation is crucial. If parkinsonian motor symptoms precede dementia by more than one year (typically several years), the appropriate diagnosis is Parkinson's with dementia, not Lewy body disease.

Delirium: Presents with acute cognitive fluctuations, but has sudden onset, short-duration fluctuating course, and identifiable cause (infection, metabolic disturbance, medication). It reverses with treatment of the underlying cause.

Vascular dementia: May present with stepwise progression and fluctuations related to vascular events, but neuroimaging shows significant cerebrovascular disease, and there are no typical visual hallucinations or prominent parkinsonism.

8. Differences with ICD-10

In ICD-10, Lewy body disease did not have its own specific code, being frequently coded as G31.8 (other specified degenerative diseases of the nervous system) or incorrectly classified under unspecified dementia. This limitation resulted in underreporting and difficulty in epidemiological tracking.

ICD-11 represents a significant advance by creating the specific code 8A22, formally recognizing Lewy body disease as a distinct nosological entity. This change reflects the accumulated scientific knowledge over the past decades regarding the pathophysiology, clinical characteristics, and epidemiological relevance of this condition.

Main changes in ICD-11:

Specific and distinct code for Lewy body disease
Clear classification within neurocognitive disorders
Precise definition based on neuropathological and clinical criteria
Explicit differentiation from other neurodegenerative dementias

Practical impact: Specific coding allows for better epidemiological tracking, facilitates clinical research, aids in resource planning in health systems, and contributes to the development of specific clinical guidelines. Healthcare professionals should familiarize themselves with the new code to ensure accurate documentation and international comparability of data.

9. Frequently Asked Questions

1. How is the definitive diagnosis of Lewy body disease made?

The definitive diagnosis is neuropathological, performed post-mortem through the identification of Lewy bodies (alpha-synuclein inclusions) in the cerebral cortex and brainstem. Clinically, the diagnosis is probabilistic, based on the presence of core features (cognitive fluctuations, visual hallucinations, parkinsonism) and suggestive features (REM sleep behavior disorder, neuroleptic sensitivity, autonomic dysfunction). The combination of clinical criteria with biomarkers (functional neuroimaging, cardiac scintigraphy) increases diagnostic accuracy, achieving sensitivity and specificity greater than 80% in specialized centers.

2. What is the temporal difference between Lewy body disease and Parkinson disease with dementia?

The "one-year rule" is fundamental: if cognitive decline occurs simultaneously or within one year after the onset of parkinsonian motor symptoms, Lewy body disease is diagnosed. If motor symptoms precede dementia by more than one year (usually several years), the appropriate diagnosis is Parkinson disease with dementia. This distinction, although arbitrary, has practical implications for clinical management and prognosis.

3. Is treatment available in public health systems?

Treatment of Lewy body disease is available in public health systems in various countries, although the availability of specific medications varies according to local resources. Cholinesterase inhibitors (rivastigmine, donepezil) are first-line treatments for cognitive symptoms and are frequently available. Low-dose levodopa can be used for motor symptoms. Non-pharmacological management, including multidisciplinary support, caregiver education, and environmental adaptations, is an essential component of treatment.

4. Why should patients with this disease not use typical antipsychotics?

Patients with Lewy body disease present severe hypersensitivity to typical antipsychotics (haloperidol, chlorpromazine), and may develop neuroleptic malignant syndrome or marked worsening of parkinsonism, extreme rigidity, decreased level of consciousness, and risk of death. This severe adverse reaction occurs due to the vulnerability of the dopaminergic system in this disease. When it is necessary to treat severe psychotic symptoms, atypical antipsychotics in very low doses (quetiapine, clozapine) may be considered with extreme caution.

5. Do cognitive fluctuations follow any predictable pattern?

Cognitive fluctuations in Lewy body disease vary among patients, but frequently present a circadian pattern, with worsening in the late afternoon and early evening (the "sundowning" phenomenon). They may last from minutes to days, with variations in attention, alertness, coherence of speech, and functional capacity. Some patients present periods of profound confusion alternating with moments of surprising lucidity. Factors such as infections, medications, sleep disturbances, and environmental changes may exacerbate fluctuations.

6. Can this code be used in medical certificates and documentation for benefits?

Yes, code 8A22 should be used in all official medical documentation, including certificates, reports for disability benefit requests, reports for tax exemption related to serious illnesses, and documentation for rehabilitation services. Precise coding is essential to ensure appropriate access to resources, social benefits, and specific health services for patients with dementia. Documentation should include detailed description of functional limitations and care needs.

7. How long does the disease progression last?

The progression of Lewy body disease is variable among individuals, but generally faster than Alzheimer disease. Mean survival after diagnosis varies between five to seven years, although some patients live more than ten years. Factors associated with faster progression include advanced age at diagnosis, presence of severe motor symptoms, recurrent falls, and significant autonomic dysfunction. The course is progressive and irreversible, with gradual functional decline requiring increasing care.

8. Is there genetic predisposition to develop this disease?

Most cases of Lewy body disease are sporadic, without clear hereditary pattern. However, approximately 10-15% of cases present family history, and mutations in specific genes (GBA, SNCA, APOE) have been associated with increased risk. The presence of a first-degree relative with Lewy body disease or Parkinson disease may slightly increase individual risk. Genetic testing is not routinely recommended for diagnosis, being reserved for cases with significant family history or for research contexts.

Conclusion

Lewy body disease represents a significant diagnostic challenge that requires in-depth knowledge of its distinctive clinical characteristics. Precise coding with ICD-11 code 8A22 is fundamental to ensure adequate documentation, facilitate clinical research, guide resource allocation, and most importantly, ensure that patients receive appropriate care. Healthcare professionals should be familiar with diagnostic criteria, differentiation from other dementias, and therapeutic peculiarities of this condition to optimize clinical management and improve the quality of life of patients and caregivers.

External References

This article was prepared based on reliable scientific sources:

References verified on 2026-02-03

Lewy Body Disease

Share